BCEIE › News › AJANTPHARM

Pledge

Ajanta Pharma: The Exchange has received revised Disclosure

Ajanta Pharma (AJANTPHARM) filed a disclosure titled "The Exchange has received revised Disclosure". The company is valued at about ₹41,936 crore.

BCEIE News Desk · Published 17 Nov 2026, 10:35 am IST · Filing received 17 Nov 2026, 10:18 am IST

What happened

Ajanta Pharma (AJANTPHARM) filed a disclosure with the exchanges on 17 November 2026 at 10:18 AM titled "The Exchange has received revised Disclosure".

Company snapshot

Ajanta Pharma is a mid-cap company in the Healthcare sector, with a market value of about ₹41,936 crore.

The stock last traded at ₹3,356, against a 52-week range of ₹2,445.8–₹3,796 (11.6% below the high).

Before this filing the shares had moved −0.5% over the month and −10.6% over three months. Average daily turnover over the last 20 sessions was about ₹59.24 crore.

Promoters held 63.47% at the end of Q2 FY27; 20.65% of promoter shares were pledged. Foreign institutions owned 7.63% and domestic institutions 21.94%.

Quarterly results (consolidated, ₹ crore)
QuarterRevenueNet profitEPS (₹)
Q2 FY261,354260.220.83
Q3 FY261,375273.821.91
Q4 FY261,422266.721.35
Q1 FY271,62633026.75
Q2 FY271,794388.131.07

What history shows

This is not the company's first pledge disclosure: BCEIE has at least 12 earlier filings of this kind on record since May 2026.

After those filings, the stock gained 0.6% on average the next trading day and was up 0.5% on average after five days (12 filings with price data).

Across 17 similar disclosures by other Healthcare companies, shares moved −1.9% on average the next day and −1.3% over five days; 24% of them rose the next day.

Market-wide, 626 pledge filings with an impact score of 50 or more saw an average next-day move of +0.7%, with 52% rising.

Past reactions describe what happened before; they are not a forecast.

Earlier filings of this kind
DateFilingNext day5 days
9 Nov 2026The Exchange has received Disclosure under Regulation 31(1) and…−0.6%—
21 Oct 2026The Exchange has received Disclosure under Regulation 31(1) and…−0.9%+4.9%
6 Oct 2026The Exchange has received Disclosure under Regulation 31(1) and…+2.4%−4.5%
28 Sept 2026The Exchange has received Disclosure under Regulation 31(1) and…+0.3%—
18 Sept 2026The Exchange has received Disclosure under Regulation 31(1) and…−1.2%−1.1%

In the news

Recent coverage elsewhere (links open the original publisher):

Source

Automatically written from the exchange filing and BCEIE data. Not investment advice. Check the original filing before acting on it.

More on Ajanta Pharma Limited